MSB 2.17% $1.13 mesoblast limited

any commentary on efficacy no longer part of the CRL.You say you...

  1. 2,749 Posts.
    lightbulb Created with Sketch. 1844
    any commentary on efficacy no longer part of the CRL.
    You say you are a physician - it's an unmet need .
    FDA acknowledges it works
    Why don't you respond with your thoughts?
    You have commented for years - all ears

    Reg
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.